HC Wainwright Has Pessimistic Outlook of ENTA Q2 Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Analysts at HC Wainwright decreased their Q2 2025 earnings estimates for Enanta Pharmaceuticals in a research note issued to investors on Tuesday, February 11th. HC Wainwright analyst E. Arce now forecasts that the biotechnology company will earn ($1.42) per share for the quarter, down from their previous estimate of ($1.32). HC Wainwright has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for Enanta Pharmaceuticals' current full-year earnings is ($5.05) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals' Q3 2025 earnings at ($1.81) EPS, Q4 2025 earnings at ($2.00) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($9.50) EPS, FY2027 earnings at ($9.80) EPS, FY2028 earnings at ($9.50) EPS and FY2029 earnings at ($8.15) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%.

Several other equities research analysts also recently issued reports on the stock. StockNews.com downgraded shares of Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday, February 11th. JMP Securities reiterated a "market outperform" rating and issued a $21.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. Finally, Robert W. Baird cut their target price on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday, November 26th. Two analysts have rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $17.25.

Enanta Pharmaceuticals Trading Down 4.8 %

Shares of ENTA stock traded down $0.36 during trading hours on Thursday, hitting $7.14. 419,301 shares of the company were exchanged, compared to its average volume of 435,589. The business has a 50 day moving average of $5.72 and a two-hundred day moving average of $9.37. Enanta Pharmaceuticals has a 52 week low of $4.71 and a 52 week high of $17.80. The company has a market capitalization of $152.30 million, a PE ratio of -1.30 and a beta of 0.54.

Insider Buying and Selling

In other news, CEO Jay R. Luly bought 45,000 shares of the firm's stock in a transaction on Wednesday, February 12th. The shares were purchased at an average cost of $5.69 per share, with a total value of $256,050.00. Following the acquisition, the chief executive officer now directly owns 846,638 shares in the company, valued at $4,817,370.22. This represents a 5.61 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 13.89% of the stock is owned by insiders.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. US Bancorp DE increased its holdings in Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company's stock valued at $45,000 after buying an additional 4,243 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in shares of Enanta Pharmaceuticals during the 4th quarter valued at approximately $26,000. Tower Research Capital LLC TRC grew its holdings in shares of Enanta Pharmaceuticals by 46.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 2,274 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Enanta Pharmaceuticals during the 4th quarter valued at approximately $58,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter valued at approximately $122,000. 94.99% of the stock is owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.